Get the Stockscreener App
8.64
1.41%
0.13
Kamada Ltd stock is traded at $8.64, with a volume of 146.49K.
It is up +1.41% in the last 24 hours and up +7.07% over the past month.
Kamada Ltd is a drug-focused, plasma-derived protein therapeutics company. It is involved in the business of developing, producing, and marketing specialty therapeutics using protein purification proprietary technology. Its product portfolio consists of Glassia, Bramitob, Foster, Ixiaro, Factor-IX, and others. The company has two segments namely, the Proprietary Products segment and the Distribution segment. It derives the majority of its revenue from the Proprietary products segment. The firm categorizes its products in Lung Disease, Vaccines, Haemophilia, Immunoglobulins, Critical care, and Diagnostics.
See More
Previous Close:
$8.51
Open:
$8.43
24h Volume:
146.49K
Relative Volume:
1.78
Market Cap:
$497.79M
Revenue:
$154.57M
Net Income/Loss:
$15.07M
P/E Ratio:
32.00
EPS:
0.27
Net Cash Flow:
$10.92M
1W Performance:
+7.61%
1M Performance:
+7.07%
6M Performance:
+15.38%
1Y Performance:
+6.68%
1-Day Range:
$8.37
$8.705
1-Week Range:
$8.02
$8.705
52-Week Range:
$5.54
$8.88
Kamada Ltd Stock (KMDA) Company Profile
Compare KMDA vs TAK, ZTS, HLN, TEVA, UTHR
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
KMDA
Kamada Ltd
|
8.63 | 490.87M | 154.57M | 15.07M | 10.92M | 0.27 |
|
TAK
Takeda Pharmaceutical Co Adr
|
18.36 | 57.75B | 29.85B | 776.90M | 4.35B | 0.2408 |
|
ZTS
Zoetis Inc
|
128.16 | 56.70B | 9.40B | 2.65B | 2.24B | 5.935 |
|
HLN
Haleon Plc Adr
|
11.19 | 49.70B | 14.26B | 1.98B | 2.47B | 0.4327 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
33.97 | 39.96B | 17.41B | 1.43B | 1.00B | 1.2182 |
|
UTHR
United Therapeutics Corp
|
478.24 | 20.49B | 3.13B | 1.27B | 1.12B | 26.39 |
Kamada Ltd Stock (KMDA) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-21-25 | Initiated | The Benchmark Company | Buy |
| Jul-03-24 | Initiated | Stifel | Buy |
| Feb-02-18 | Initiated | Chardan Capital Markets | Buy |
Kamada Ltd Stock (KMDA) Latest News
Weekly Earnings: Is Kamada Ltd stock a buy or sellWeekly Earnings Recap & Intraday High Probability Setup Alerts - baoquankhu1.vn
Sentiment Review: Is Kamada Ltd exposed to political riskCEO Change & AI Optimized Trading Strategy Guides - baoquankhu1.vn
Kamada Ltd. (NASDAQ:KMDA) Short Interest Update - MarketBeat
Is Kamada Ltd exposed to political riskWeekly Trading Summary & AI Powered Market Entry Strategies - baoquankhu1.vn
Aug Intraday: Can Kamada Ltd navigate macro headwindsPortfolio Return Report & Daily Profit Maximizing Tips - baoquankhu1.vn
Kamada (TLV:KMDA) shareholder returns have been favorable, earning 74% in 3 years - simplywall.st
Can Kamada Ltd. continue delivering strong returnsJuly 2025 Gainers & Verified Chart Pattern Signals - mfd.ru
Pharma News: Will Kamada Ltd outperform the market in YEAR2025 Short Interest & Weekly Top Stock Performers List - baoquankhu1.vn
Kamada (KMDA) Soars 8.1%: Is Further Upside Left in the Stock? - Yahoo Finance
Volume Summary: Is Kamada Ltd a potential multi baggerTrade Entry Summary & Reliable Breakout Stock Forecasts - baoquankhu1.vn
Kamada Ltd. (KMDA) Stock Analysis: Exploring a 62.91% Upside Potential in the Healthcare Sector - DirectorsTalk Interviews
Kamada Ltd: Biopharma under Pressure as KMDA Stock Tests Investor Patience - AD HOC NEWS
Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market - openPR.com
Is Kamada Ltd. stock a safe investment in uncertain marketsSector ETF Performance & Fast Growing Trading Plans - Bollywood Helpline
Kamada Ltd. (KMDA) Stock Analysis: Exploring A 58.15% Upside In The Healthcare Space - DirectorsTalk Interviews
Kamada Targets 13% Revenue Growth And 23% Adjusted EBITDA Growth In 2026 Driven By Its Diverse Commercial Portfolio | Corporate - EQS News
Kamada Targets 13% Revenue Growth And 23% Adjusted EBITDA Growth In 2026 Driven By Its Diverse Commercial Portfolio - NewMediaWire
Kamada Projects Strong 2026 Growth Fueled by Plasma Portfolio and Distribution Expansion - citybuzz -
Kamada shares climb after upbeat 2026 outlook points to double-digit growth - MSN
HC Wainwright Issues Optimistic Forecast for Kamada Earnings - Defense World
Kamada shares drop as company halts Phase 3 study of inhaled AAT therapy - MSN
Q1 Earnings Forecast for Kamada Issued By HC Wainwright - Defense World
Kamada Ltd. (KMDA) Stock Analysis: Unpacking a 63.52% Potential Upside in Healthcare Innovation - DirectorsTalk Interviews
Q1 Earnings Estimate for Kamada Issued By HC Wainwright - MarketBeat
Can Kamada Ltd. stock attract ESG capital inflowsMarket Performance Recap & Low Drawdown Momentum Trade Ideas - Улправда
Benchmark reiterates Buy rating on Kamada stock, maintains $15 target By Investing.com - Investing.com Nigeria
Benchmark reiterates Buy rating on Kamada stock, maintains $15 target - Investing.com
Kamada 2025/2026 Outlook: Evaluating Revenue Growth And Product Drivers (NASDAQ:KMDA) - Seeking Alpha
Kamada (KMDA) Projects Strong Revenue and EBITDA Growth by 2026 - GuruFocus
Kamada forecasts double-digit profitable growth in 2026 - MSN
Kamada stock rises after issuing 2026 guidance showing double-digit growth - Investing.com Nigeria
Kamada stock rises after issuing 2026 guidance showing double-digit growth By Investing.com - Investing.com South Africa
Kamada forecasts 13% revenue growth in 2026, issues guidance - Investing.com
Kamada forecasts 13% revenue growth in 2026, issues guidance By Investing.com - Investing.com Nigeria
Kamada Provides 2026 Annual Guidance of $200$205 Million in Revenues and $50$53 Million of Adjusted EBITDA, Representing Double-Digit Growth and Affirms 2025 Financial Guidance - marketscreener.com
Kamada (NASDAQ:KMDA) Stock Crosses Above 50 Day Moving AverageHere's Why - MarketBeat
Kamada Ltd. (KMDA) Stock Analysis: Unearthing an 84% Upside Potential in the Healthcare Sector - DirectorsTalk Interviews
Leasing LimitedFundamental Strength Indicators & Free Exceptional ROI Methods - bollywoodhelpline.com
Kamada (NASDAQ:KMDA) Shares Pass Above 50-Day Moving AverageTime to Sell? - MarketBeat
Kamada (NASDAQ:KMDA) Shares Pass Above 50-Day Moving Average – Time to Sell? - Defense World
Kamada (KMDA) price target decreased by 11.86% to 13.26 - MSN
Kamada (KMDA) Stock Analysis Report | Financials & Insights - Benzinga
Kamada Ltd.(NasdaqGS: KMDA) added to NASDAQ Biotechnology Index - marketscreener.com
Is Kamada Ltd. stock affected by interest rate hikesInsider Selling & Long-Term Growth Plans - Улправда
Kamada Ltd Stock (KMDA) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.56%
10.18%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):